Tocilizumab Associated With Improved Anemia Markers in Patients With Rheumatoid Arthritis
Other biologic DMARDs were not associated with any significant clinically meaningful increase in Hb and Hct levels.
Other biologic DMARDs were not associated with any significant clinically meaningful increase in Hb and Hct levels.
Tocilizumab therapy showed rapid improvement in ocular parameters for uveitis in juvenile idiopathic arthritis patients.
Cohort study of patients with rheumatoid arthritis who newly initiated tocilizumab or tumor necrosis factor inhibitor therapy using multi-database claims data.
Prospective observational study yields patients with hepatitis B reactivation, but all were asymptomatic.
FDA will fast track review of nonsteroidal treatment option for giant cell arteritis.
Pooled results examine the incidence of antidrug antibody development after both intravenous and subcutaneously administered tocilizumab for rheumatoid arthritis.
New research pools data from several clinical trials to examine whether tocilizumab-associated neutropenia was linked to increased risk for serious infection in patients with rheumatoid arthritis.
Long-term efficacy and safety data indicated tocilizumab monotherapy as an option for patients who do not tolerate methotrexate.
Data from a large German cohort found a greater risk for lower intestinal perforation with tocilizumab as compared with conventional synthetic disease-modifying antirheumatic drug therapy for rheumatoid arthritis (RA).
Tocilizumab was associated with significant improvement in periodontal inflammation in patients with RA.